Summary:
This podcast features a panel discussion from the 2023 PODD: Partnership Opportunities in Drug Delivery Conference on achieving targeted delivery of gene editing therapies including:
- Effectively delivering larger gene editing therapies to both the right tissue and intracellularly with fewer off target effects
- Viral and non-viral delivery approaches, their strengths and weaknesses
- Next-generation hybrid delivery approaches
To learn more about the PODD conference, please visit PODDConference.com.
Speakers
Liping Zhou, PhD
Senior Director, Advanced Drug Delivery
AstraZeneca
Sean Bedingfield, PhD
Director - Genetic Medicine
Eli Lilly and Company
Shawn Davis, PhD
CEO
Liberate Bio
Sanyogitta Puri, PhD
Sr Director, RNA & Gene Therapies - Non-Viral Delivery
Novo Nordisk
Manmohan Singh, PhD
CTO
Beam Therapeutics
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.